Gwendolyn Binder-Scholl
Director Técnico/Científico/I+D en CABALETTA BIO, INC. .
Fortuna: 243 600 $ al 30/04/2024
Perfil
Gwendolyn Binder-Scholl is an Independent Director at Instil Bio, Inc. since 2020 and the President-Science & Technology at Cabaletta Bio, Inc. since 2019.
She previously worked as the Director-Scientific Affairs at VIRxSYS Corp.
from 2002 to 2005 and as the Director-Translational Research Operations at the University of Pennsylvania from 2006 to 2011.
She also served as the Executive Vice President at Adaptimmune LLC.
From 2011 to 2019, she held the position of Chief Technology Officer at Adaptimmune Therapeutics Plc.
Dr. Binder-Scholl holds a doctorate degree from The Johns Hopkins University, which she obtained in 2002.
She completed her undergraduate studies at Wells College.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
CABALETTA BIO, INC.
0.04% | 04/04/2024 | 20 000 ( 0.04% ) | 243 600 $ | 30/04/2024 |
INSTIL BIO, INC.
-.--% | 16/04/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Cargos activos de Gwendolyn Binder-Scholl
| Empresas | Cargo | Inicio |
|---|---|---|
| CABALETTA BIO, INC. | Director Técnico/Científico/I+D | 01/02/2019 |
| INSTIL BIO, INC. | Director/Miembro de la Junta | 01/07/2020 |
Antiguos cargos conocidos de Gwendolyn Binder-Scholl.
| Empresas | Cargo | Fin |
|---|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Director Técnico/Científico/I+D | 31/01/2019 |
| University of Pennsylvania | Corporate Officer/Principal | 01/01/2011 |
VIRxSYS Corp.
 VIRxSYS Corp. BiotechnologyHealth Technology VIRxSYS Corp. is a holding company, which uses its proprietary platform technologies to develop therapies for serious human diseases. Its platform technologies include lentiviral vectors as a delivery vehicle for genes against certain diseases and for vaccine therapies. Its therapies are in various stages of development from pre-clinical through Phase II clinical trials. The company was founded by Boro Dropulic, William J. Turner, and Wiliam N. Sick Jr in 1998 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | 01/01/2005 |
Adaptimmune LLC
 Adaptimmune LLC Medical/Nursing ServicesHealth Services Part of Adaptimmune Therapeutics Plc, Adaptimmune LLC is a company that focuses on the use of T cell therapy to treat cancer and infectious disease. The company is based in Philadelphia, PA. | Corporate Officer/Principal | - |
Formación de Gwendolyn Binder-Scholl.
| The Johns Hopkins University | Doctorate Degree |
| Wells College | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| INSTIL BIO, INC. | Health Technology |
| ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
| Empresas privadas | 3 |
|---|---|
VIRxSYS Corp.
VIRxSYS Corp. BiotechnologyHealth Technology VIRxSYS Corp. is a holding company, which uses its proprietary platform technologies to develop therapies for serious human diseases. Its platform technologies include lentiviral vectors as a delivery vehicle for genes against certain diseases and for vaccine therapies. Its therapies are in various stages of development from pre-clinical through Phase II clinical trials. The company was founded by Boro Dropulic, William J. Turner, and Wiliam N. Sick Jr in 1998 and is headquartered in Gaithersburg, MD. | Health Technology |
| Cabaletta Bio, Inc. | |
Adaptimmune LLC
Adaptimmune LLC Medical/Nursing ServicesHealth Services Part of Adaptimmune Therapeutics Plc, Adaptimmune LLC is a company that focuses on the use of T cell therapy to treat cancer and infectious disease. The company is based in Philadelphia, PA. | Health Services |
- Bolsa de valores
- Insiders
- Gwendolyn Binder-Scholl
